Paraneoplastic syndromes (PNS) are complex disorders triggered by cancer, not by direct tumor effects. They arise from hormones or immune responses initiated by tumors, particularly in lung cancer.

Lung cancer is a leading cause of cancer deaths worldwide, with Chennai seeing high incidence rates.

The Chennai study highlights that most lung cancer patients with PNS are aged 50-60, predominantly male.

Among the observed syndromes in the study, syndrome of inappropriate antidiuretic hormone secretion (SIADH) and humoral hypercalcemia of malignancy (HHM) are noteworthy.

Paraneoplastic syndromes can also lead to neurologic symptoms like Lambert-Eaton syndrome and hematologic issues including anemia.

Recognizing paraneoplastic syndromes early is crucial for lung cancer diagnosis, positively influencing outcomes. Treatment typically focuses on managing the underlying cancer along with symptom relief to enhance patient quality of life.

Future efforts must focus on raising awareness about PNS and conducting further research on their mechanisms.